Related Experiment Video

Updated: Jun 4, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Emerging oral therapies for multiple sclerosis

Colleen E Miller1, Margaret A Umhauer

  • 1William C. Baird Multiple Sclerosis Research Center, Jacobs Neurological Institute, University at Buffalo, The State University of New York, Buffalo, NY, USA. cmiller@TheJNI.org

The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses
|February 23, 2011
PubMed

Insights

New oral therapies for multiple sclerosis (MS) offer potential benefits but require careful patient monitoring. Nurses are crucial in educating patients about these emerging treatments and managing their care.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) management has advanced, yet improved therapies are needed.
  • Existing treatments for MS have limitations in efficacy, safety, convenience, and tolerability.
  • A new wave of oral medications for MS is under investigation.

Purpose of the Study:

  • To review recently approved and investigational oral therapies for multiple sclerosis (MS).
  • To highlight the evolving role of nurses in patient education and monitoring for new MS treatments.

Main Methods:

  • Review of recently approved oral multiple sclerosis (MS) therapies.
  • Analysis of oral MS therapies currently in development or under FDA review.
  • Discussion of nursing implications for patient education and monitoring.

Main Results:

  • Several oral therapies for multiple sclerosis (MS) have been approved or are in development.
  • Emerging data necessitate ongoing evaluation of benefits and risks for these novel treatments.
  • Nurses are essential in guiding patients through treatment decisions and monitoring outcomes.

Conclusions:

  • Oral therapies represent a significant development in multiple sclerosis (MS) treatment.
  • Continuous data evaluation is vital for understanding the efficacy and safety profiles of new oral MS drugs.
  • The role of nurses in patient education, safety monitoring, and adherence support is paramount for successful MS management with new oral agents.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...